- The following slides provide an overview of the oncolytic virus-relevant abstracts presented at the AACR 2022 Annual Meeting, with comparisons of variables such as; clinical vs preclinical data, viral family, disease indications and phase of development.
- A total of 37 distinct drugs were evaluated across the 46 abstracts, with 31 drugs belonging to the oncolytic virus therapeutic class and 6 being viral vaccines. Find out more by downloading the sample report.
Find out more
This insight and data is part of the subscription to Beacon Oncolytic Viruses.
Speak with our Team
Our dedicated team can help you with questions by showing you how this insight and data is collated on Beacon.
About Beacon Targeted Therapies
We are a clinical trial and pipeline database solution, designed in partnership with pharmaceutical professionals. We track targeted therapies to provide accurate, in-depth and real-time information in the rapidly evolving landscape of drug development.
Learn more about how our clinical trials and drug database solutions can be tailored to your research requirements